Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-23
1997-12-09
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31335
Patent
active
056961537
ABSTRACT:
A method for administration of taxol by infusing taxol over a duration of 60 to 180 minutes for a pluratily of times during a 21 day period, each of said times being separated by an interval of between 4 to 5 days.
REFERENCES:
A Phase I Trial of Taxol Given by a 6-Hour Intravenous Infusion T. Brown, Journal of Clinical Oncology, vol. 9, No. 7 (Jul.) 1991; pp.1261-1267.
Annual Report to the Food and Drug Administration--Taxol, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, Feb. 1989.
Phase I Trial of Taxol in Patients with Advanced Cancer, R. Donehower et al, Cancer Treatment Reports, vol. 71, No. 12, Dec. 1987.
Phase I Study of Taxol Administered as a Short Iv Infusion Daily for 5 Days, J. Grem et al, Cancer Treatment Reports, vol. 71, No. 12, Dec. 1987.
Phase I Trial of Taxol Given as a 3-Hour Infusion every 21 Days, M. Kris et al. Cencer Treatment Reports, vol. 70, No. 5, May 1986.
Taxol Produces a Predominantly Sensory Neuropathy, R.B. Lipton et al, Neurology, 1989; 30:368-373.
High-Performance Liquid Chromatographic Assay for Taxol in Human Plasma and Urine and Pharmacokinetics in a Phase I Trial, S. Longnecker et al, Cancer Treatment Reports, vol.71, No. 1, Jan. 1987.
Taxol: An Important New Drug in the Management of Epithelial Ovarian Cancer, M. Markman, The Yale Journal of Biology and Medicine, Inc., 64 (1991), 583-590.
Taxol: A new agent active in melanoma and ovarian cancer, A. Einzig et al., New Drugs, Concepts and Results in Cancer Chemotheraphy, vol. 58, 1991.
Taxol: Twenty Years Later, the Story Unfolds, E. Rowinsky et al, Jourrnal of the National Cancer Institute, vol.83, No. 24, Dec. 18, 1991.
Taxol: A Novel Investigational Antimicrotubule Agent, E. Rowinsky et al, Review, vol. 82, No. 15, Aug. 1, 1990.
Cardiac Disturbances During the Administration of Taxol, E. Rowinsky et al, Journal of Clinical Oncology, vol. 9, No. 9 (Sep. 1991) pp. 1692-1703.
New Natural Products in Cancer Chemotherapy, W.Slichenmyer et al., Journal of Clinical Pharmacol, 1990; 30:770-788.
Taxol: A new and Effective anti-cancer drug, W. Slichenyer et al., Anti-Cancer Drugs, vol. 2, 1991.
Hypersenitivity Reactions from Taxol, R. Weiss et al, Journal of Clinical Oncology, vol. 8, No. 7 (Jul. 1990) pp. 1263-1268.
Phase I Clinical and Pharmacokinetic Study of Taxol, P. Wiernik et al, Cancer Research, 47, 2486-2493, May 1, 1987.
Ainsworth Sterling K.
Helson Lawrence
Goldberg Jerome D.
Martin Timothy J.
NaPro BioTherapeutics, Inc.
LandOfFree
Therapeutic regimen for treating patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic regimen for treating patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic regimen for treating patients will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1608141